Company news
Arrowhead Pharmaceuticals, Inc. news in 2019
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
December 19, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
December 15, 2019
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
December 12, 2019
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
December 10, 2019
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
December 5, 2019
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
December 3, 2019
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
December 1, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
November 25, 2019
Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
November 24, 2019
Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
November 17, 2019
Arrowhead Pharmaceuticals Announces Planned Management Transition
November 14, 2019
Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
November 10, 2019
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
November 7, 2019
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
October 30, 2019
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
October 17, 2019
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
October 1, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
September 29, 2019
Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
September 15, 2019